OBJECTIVES: In this study, we analyzed the PTEN expression in a large collection of clear cell adenocarcinomas of the ovary. Furthermore, we analyzed the expression of cyclin D1 and p27, and investigated the correlation among all these variables. METHODS: Totally, 40 clear cell adenocarcinomas were included in this study. The protein expression of PTEN, cyclin D1 and p27 was investigated by immunohistochemistry. RESULTS: Of 40 clear cell adenocarcinomas, 15 (37.5%) lost all PTEN immunoreactivity. There was no significant correlation between PTEN expression and clinical stage. Cyclin D1 expression and loss of p27 expression were detected in 16/40 (40.0%) and 14/40 (35.0%) clear cell adenocarcinoma cases. There was no significant correlation between PTEN expression and cyclin D1 or p27 protein expression. CONCLUSIONS: Loss of PTEN expression is relatively common and both cyclin D1 and p27 expressions are not related with PTEN inactivation in clear cell adenocarcinoma of the ovary.
OBJECTIVES: In this study, we analyzed the PTEN expression in a large collection of clear cell adenocarcinomas of the ovary. Furthermore, we analyzed the expression of cyclin D1 and p27, and investigated the correlation among all these variables. METHODS: Totally, 40 clear cell adenocarcinomas were included in this study. The protein expression of PTEN, cyclin D1 and p27 was investigated by immunohistochemistry. RESULTS: Of 40 clear cell adenocarcinomas, 15 (37.5%) lost all PTEN immunoreactivity. There was no significant correlation between PTEN expression and clinical stage. Cyclin D1 expression and loss of p27 expression were detected in 16/40 (40.0%) and 14/40 (35.0%) clear cell adenocarcinoma cases. There was no significant correlation between PTEN expression and cyclin D1 or p27 protein expression. CONCLUSIONS: Loss of PTEN expression is relatively common and both cyclin D1 and p27 expressions are not related with PTEN inactivation in clear cell adenocarcinoma of the ovary.
Authors: Kathryn M Kinross; Karen G Montgomery; Margarete Kleinschmidt; Paul Waring; Ivan Ivetac; Anjali Tikoo; Mirette Saad; Lauren Hare; Vincent Roh; Theo Mantamadiotis; Karen E Sheppard; Georgina L Ryland; Ian G Campbell; Kylie L Gorringe; James G Christensen; Carleen Cullinane; Rodney J Hicks; Richard B Pearson; Ricky W Johnstone; Grant A McArthur; Wayne A Phillips Journal: J Clin Invest Date: 2012-01-03 Impact factor: 14.808
Authors: L P Madhubhani P Hemachandra; Dong-Hui Shin; Usawadee Dier; James N Iuliano; Sarah A Engelberth; Larissa M Uusitalo; Susan K Murphy; Nadine Hempel Journal: Cancer Res Date: 2015-09-10 Impact factor: 12.701
Authors: Joseph J Caumanns; Katrien Berns; G Bea A Wisman; Rudolf S N Fehrmann; Tushar Tomar; Harry Klip; Gert J Meersma; E Marielle Hijmans; Annemiek M C Gennissen; Evelien W Duiker; Desiree Weening; Hiroaki Itamochi; Roelof J C Kluin; Anna K L Reyners; Michael J Birrer; Helga B Salvesen; Ignace Vergote; Els van Nieuwenhuysen; James Brenton; E Ioana Braicu; Jolanta Kupryjanczyk; Beata Spiewankiewicz; Lorenza Mittempergher; René Bernards; Ate G J van der Zee; Steven de Jong Journal: Clin Cancer Res Date: 2018-04-23 Impact factor: 12.531